Plain-English translation of NCT06949228 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether , a clot-dissolving medication, can help people recover better from a specific type of stroke. You would be eligible if you've had a large blood clot in your brain's main blood vessels and have already received emergency mechanical thrombectomy (a procedure to physically remove the clot). The trial will compare patients who receive this medication during their emergency care to those who receive standard treatment alone.
Even after emergency clot removal, some patients don't fully restore blood flow to their brain tissue, which can limit their recovery. Researchers want to see if adding this medication directly into the brain's blood vessels can improve blood flow and help patients recover better.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to receive either or standard care during your emergency stroke treatment. The medication (if assigned) is given directly into your brain's blood vessels during your emergency procedure—you won't need extra hospital visits for this. You will then be monitored closely in the hospital and asked to return for a follow-up evaluation at 90 days after your stroke to assess your recovery and any side effects.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States
Phase
Large-scale testing
Sponsor
ProMedica Health System
Enrollment target
~132 participants
Started
July 2025
Primary completion
May 2028
Age range
18 Years – 85 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Syed Fazal Zaidi, MD
ProMedica Health System
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.